Why there is no single price
People search for “the cost of Ozempic” expecting one number, and there isn’t one. The same medication, from the same pharmacy, on the same day, can cost two people wildly different amounts. Four things drive that gap:
- What the drug is approved to treat. The single biggest factor. Ozempic and Mounjaro are approved for type 2 diabetes; Wegovy and Zepbound are approved for chronic weight management. Insurers treat those two categories very differently, and many plans that readily cover a diabetes medication exclude weight-management medications entirely.
- Your insurance type. Commercial, Medicare, Medicaid, or none — each puts you on a different pathway with different rules, as the tool above sets out.
- Your specific plan’s formulary. Two people with commercial insurance from different employers can face completely different costs for the same drug.
- Which savings programmes you can use. This is where the largest avoidable losses happen, because the eligibility rules are counterintuitive.
Buying direct is often far cheaper than the list price
The headline list prices are not what most people pay, and the gap is large. Both manufacturers now sell direct to patients at a substantial discount for people paying cash:
| Medication | Self-pay, direct from manufacturer | Published list price |
|---|---|---|
| Wegovy | From $149 (tablets) / $299 (pens) | $1,349 |
| Ozempic | From $349 | $1,028 |
| Zepbound | $299–$449 (KwikPen, by dose) | — |
| Mounjaro | $499 | — |
The practical implication is worth stating plainly: if you are paying cash, check the manufacturer’s own pharmacy before your local one. The difference between the list price and the self-pay price can be several hundred dollars a month for the identical product.
List prices are falling in 2027
Novo Nordisk announced on 24 February 2026 that the list price of Wegovy, Ozempic and Rybelsus will drop to $675 per month from 1 January 2027 — roughly a 50% cut for Wegovy and 35% for Ozempic. The company states this does not change direct-to-patient self-pay prices, which are already lower.
The savings-card rule that catches people out
If you have Medicare or Medicaid, manufacturer copay cards are off the table
Federal rules prohibit drug manufacturers from offering copay or savings cards to people with government insurance. Manufacturer terms state this explicitly — government beneficiaries are excluded. It is not your plan being difficult and not something a pharmacist can override, and it applies regardless of your income. People regularly discover this at the pharmacy counter after budgeting around an advertised “as little as $25” figure they were never eligible for.
If that applies to you, the routes that remain are genuinely different in kind: the Medicare GLP-1 Bridge programme described below, patient-assistance programmes run by manufacturers (means-tested, and separate from savings cards), Medicare’s Extra Help programme, and state pharmaceutical assistance programmes.
The Medicare GLP-1 Bridge programme
This is new and significant. Since 1 July 2026, eligible Medicare Part D enrollees can get certain weight-management GLP-1s for a flat $50 per month through a programme called the Medicare GLP-1 Bridge. That matters because Part D has historically been unable to cover medications prescribed solely for weight loss.
- Covered: Wegovy (injection or tablet), Zepbound (KwikPen only), and Foundayo (tablet).
- Not covered: Zepbound single-dose pens and Zepbound vials — the formulation matters, so check which one your prescription specifies.
- To qualify: enrolment in a participating Part D plan, a BMI of 35 or higher (or 27 or higher with a qualifying related condition), and prior authorisation.
Three caveats that are easy to miss, and each of them costs money:
- Plan participation is voluntary. Your Part D plan may simply not take part, so ask before assuming.
- The $50 does not count toward your Part D deductible or your annual out-of-pocket cap.
- Low-income subsidies cannot be applied to bridge-programme prescriptions.
It is also a time-limited programme with a successor model planned, so confirm the current end date and your plan’s participation directly with Medicare and your plan rather than relying on any published summary, including this one.
If your claim is denied
A denial is a starting position, not a verdict. Prior-authorisation denials are frequently overturned on appeal when the prescriber supplies clinical documentation — your diagnosis, previous treatments tried, comorbidities, and why this medication is appropriate. Ask your prescriber’s office directly whether they will file an appeal; many have staff who do this routinely.
Practical points that improve the odds:
- Ask for the denial reason in writing — the specific criterion you failed matters.
- Ask what the plan’s documented approval criteria actually are, then address them point by point.
- Ask whether a formulary exception or a step-therapy exception is the right route.
- Note the appeal deadline, which is usually strict.
A warning about unusually cheap sources
Be careful what you buy
- Products sold well below the going rate, particularly from websites that do not require a prescription, may not be the FDA-approved medication at all.
- Compounded semaglutide and tirzepatide are not FDA-approved products. They are not reviewed for safety, effectiveness, or quality, and dosing errors with them have caused documented harm.
- “Research chemical” or grey-market peptides sold online are not medicines and are not intended for human use.
- If a price seems impossible, treat that as information. Verify the pharmacy is licensed before buying.
Questions worth asking before you start
Cost is a legitimate part of a treatment decision, not a separate administrative matter. Because these medications generally need to be taken long-term to maintain their effect, affordability over months and years matters more than the first month’s price. Worth raising with your prescriber:
- Is there an alternative in this class my plan covers better?
- If my savings card has a cap or expiry, what happens to my cost after that?
- What happens if I have to stop for cost reasons — and what should I expect?
On that last point, see how GLP-1 medications work — the appetite effect depends on the drug being present, so stopping generally means appetite returns.
More cost guides
Dedicated guides on paying without insurance, navigating coverage appeals, and comparing costs across the class are being written and will be linked here as they are published.
Sources
Each source below supports specific statements on this page. We cite the strongest available authority and verify against the current version before publishing.
- Wegovy cost, coverage and savings informationNovoCare, Novo NordiskSupports: Wegovy and Ozempic self-pay pricing, savings-card terms, and the exclusion of government beneficiaries. Verified 25 July 2026.
- Zepbound coverage and savingsEli Lilly and CompanySupports: Zepbound self-pay pricing by dose, savings-card terms and caps, and government-insurance exclusions. Verified 25 July 2026.
- Novo Nordisk announces significant reduction in US list price for Wegovy, Ozempic and RybelsusNovo NordiskSupports: The $675 list price effective 1 January 2027, announced 24 February 2026.
- Medicare GLP-1 Bridge: GLP-1 drugs for $50 a monthMedicare.gov, Centers for Medicare & Medicaid ServicesSupports: The Medicare GLP-1 Bridge programme: covered products, eligibility, and cost-sharing rules.
- FDA-approved prescribing information (drug labels)DailyMed, U.S. National Library of MedicineSupports: Approved indications for each product, which determine coverage eligibility.
This page is general education, not medical advice. Talk to your own healthcare provider about your situation before starting, stopping, or changing any medication.